Loading...
•
Jun 30, 2024
Bio-Techne Q4 2024 Earnings Report
Bio-Techne's Q4 2024 financial performance reflected solid results amidst stabilizing end-markets.
Key Takeaways
Bio-Techne reported a 2% increase in net sales for the fourth quarter of fiscal year 2024, reaching $306.1 million. GAAP EPS was $0.25, while adjusted EPS was $0.49. The Diagnostics & Genomics segment showed strong growth, with a 15% increase in net sales.
Organic revenue increased by 1% (2% reported) to $306.1 million.
GAAP EPS was $0.25 versus $0.47 one year ago; adjusted EPS was $0.49 compared to $0.55 one year ago.
Diagnostics & Genomics segment achieved 9% organic growth (15% reported).
Adjusted operating margin was 33.5%, representing a 50 basis-point sequential improvement.
Revenue by Segment
Forward Guidance
No specific forward guidance was provided in the release.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...